文献速递贫血与红细胞疾病白血病MDS 与骨髓增殖性肿瘤

遗传性血小板减少症伴恶性肿瘤风险的临床、血小板及遗传特征分析

Insights into the clinical, platelet and genetic landscape of inherited thrombocytopenia with malignancy risk.
PubMed 文献 · Br J Haematol · 2025-07-16

该研究评估了37例RUNX1相关血小板减少症(RT)、9例ETV6-RT和20例ANKRD26-RT患者的临床、血小板及分子特征。遗传诊断在发现血小板减少后延迟约20年。约三分之一病例发生恶性肿瘤,包括MDS、AML、CML Ph+、B-ALL Ph+及乳腺癌等。

要点

  • RUNX1、ETV6或ANKRD26胚系变异相关IT-HM的血液系统恶性肿瘤风险为10%-45%。
  • 遗传诊断在发现血小板减少后延迟约20年。
  • 约三分之一病例发生恶性肿瘤,包括MDS、AML、CML Ph+、B-ALL及乳腺癌。

核心结论

  • RUNX1、ETV6或ANKRD26胚系变异相关遗传性血小板减少症具有10%-45%的血液系统恶性肿瘤风险。
  • 恶性肿瘤高发生率凸显了在生命早期进行早期诊断的重要性。

研究设计与样本

  • 研究纳入37例RUNX1相关血小板减少症(RUNX1-RT)、9例ETV6-RT和20例ANKRD26-RT患者,评估其临床、血小板及分子特征。

主要发现

  • 遗传诊断在发现血小板减少后延迟约20年。
  • RUNX1-RT和ANKRD26-RT患者中25%-30%存在出血倾向。
  • 所有患者中90%存在血小板聚集功能受损,而活化和颗粒分泌减少呈异质性。
  • 大多数RUNX1-RT患者GPIa水平低,可能是有用的疾病生物标志物。
  • 鉴定出RUNX1基因16种、ETV6基因4种和ANKRD26基因4种不同的遗传变异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inherited thrombocytopenia (IT) with germline variants in RUNX1, ETV6 or ANKRD26 carries a high risk (10%-45%) of developing haematological malignancy (IT-HM). We evaluated the clinical, platelet and molecular characteristics in 37 patients with RUNX1-related thrombocytopenia (RT), 9 with ETV6-RT and 20 with ANRKD26-RT. Genetic diagnosis was delayed by about 20 years from the identification of thrombocytopenia. Bleeding tendency was present in 25%-30% of RUNX1-RT and ANKRD26-RT patients. Platelet aggregation was impaired in 90% of all patients, while reduced activation and granule secretion were heterogeneous. Most RUNX1-RT patients had low glycoprotein Ia (GPIa) levels, which may be a useful disease biomarker. Sixteen distinct genetic variants in RUNX1, four in ETV6 and four in ANKRD26 were identified in patients. The clinical profile showed immune, skin, gastrointestinal and other comorbidities in many patients. One third of the cases developed a malignancy: This included eight RUNX1-RT patients with myelodysplastic syndrome (MDS), five with acute myeloid leukaemia (AML), and one with chronic myeloid leukaemia (CML) Ph+. One patient with ETV6-RT subsequently developed B-cell acute lymphoblastic leukaemia (B-ALL) during childhood. Three cases with ANKRD26-RT demonstrated a multifaceted clinical presentation, including B-ALL Ph+, MDS and breast cancer. The high incidence of HM development highlights the importance of early diagnosis in life.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Marín-Quílez A, Sánchez-Fuentes A, Zamora-Cánovas A, et al. Insights into the clinical, platelet and genetic landscape of inherited thrombocytopenia with malignancy risk. Br J Haematol. 2025. PMID: 40670159. doi:10.1111/bjh.70001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。